Analysis of the AMH rs10407022 Polymorphism Reveals Monomorphism in an Iranian IVF Cohort Consistent with POSEIDON Stratification Criteria: A Case-Control Study

Document Type : Original Article

Authors

1 Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Department of Biology, Science and Arts University, Yazd, Iran

3 Dr. Mazaheri’s Medical Genetics Lab, Yazd, Iran

Abstract

Background: Poor ovarian response (POR) during in vitro fertilization (IVF) remains a major challenge, adversely affecting both the emotional wellbeing of patients and clinical outcomes. Genetic polymorphisms, particularly in the anti Müllerian hormone (AMH) gene, such as rs10407022, have been suggested to contribute to POR. This study aimed to investigate the association between the rs10407022 polymorphism and POR, as defined by the POSEIDON criteria, among Iranian women.
Methods: In this analytical case-control study, 232 women under 45 years with poor ovarian response according to the POSEIDON criteria and 56 women with normal ovarian response (controls) were included. Demographic, hormonal, and ovarian reserve parameters, including age, BMI, FSH, AMH, and AFC, were recorded. Genotyping of the AMH rs10407022 (G/T) polymorphism was performed using ARMS-PCR, and associations were assessed using logistic regression adjusted for age and BMI.
Results: Cases exhibited significantly lower AMH levels (0.9 ± 0.4 ng/mL vs. 2.6 ± 0.8 ng/mL, p < 0.001), lower AFC, and higher day 3 FSH compared to controls. Notably, all participants in both groups had only the GT genotype for rs10407022, with no GG or TT genotypes observed. This finding indicates that the rs10407022 locus was monomorphic in this Iranian cohort, precluding any significant association with POR.
Conclusion: The AMH rs10407022 polymorphism was monomorphic in this Iranian population, exhibiting only the GT genotype. While significant differences in hormonal markers were observed between POR and normal responders, this single nucleotide polymorphism (SNP) did not account for the variability in ovarian response. Further large-scale, multiethnic studies are warranted to elucidate the genetic underpinnings of POR.

Keywords

References

  1. Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization. Hum Reprod 2011; 26(7): 1616-24.
  2. Busnelli A. The burden of poor ovarian response on women and society. Fertil Steril 2020; 114(5): 921-32.
  3. Esteves SC, Andersen CY, Fischer R, Humaidan P, Alviggi C. The POSEIDON criteria: a new classification for low prognosis patients in ART. Front Endocrinol (Lausanne) 2021; 12: 719647.
  4. Roque M, Haahr T, Esteves SC, Humaidan P. The POSEIDON stratification - moving from poor ovarian response to low prognosis. JBRA Assist Reprod 2021; 25(2): 282-292.
  5. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers. Hum Reprod Update 2014; 20(1): 124-40.
  6. Kevenaar ME, Laven JSE, Fong SL, Uitterlinden AG, de Jong FH, Themmen APN, et al. A functional anti-Müllerian hormone gene polymorphism is associated with follicle number and outcome in IVF. J Clin Endocrinol Metab 2008; 93(12): 4800-6.
  7. Josso N, di Clemente N, Gouédard L. Anti-Müllerian hormone and its receptors. Mol Cell Endocrinol 2001; 179(1-2): 25-32.
  8. Chen D, Zhu X & Wu Can polymorphisms of AMH/AMHR2 affect ovarian stimulation outcomes? A systematic review and meta-analysis. J Ovarian Res 2020; 13, 103.
  9. Čuš M, Vlaisavljević V, Repnik K, Potočnik U, Kovačič B. Could polymorphisms of some hormonal receptor genes, involved in folliculogenesis help in predicting patient response to controlled ovarian stimulation? J Assist Reprod Genet 2019; 36(1): 47-55.
  10. Wu CH, Yang SF, Tsao HM, Chang YJ, Lee TH, Lee MS. Anti-Müllerian Hormone Gene Polymorphism is Associated with Clinical Pregnancy of Fresh IVF Cycles. Int J Environ Res Public Health 2019; 16(5): 841.
  11. Chinta P, Antonisamy B, Mangalaraj AM, Kunjummen AT, Kamath MS. POSEIDON classification and the proposed treatment options for groups 1 and 2: time to revisit? A retrospective analysis of 1425 ART cycles. Hum Reprod Open 2021; 2021(1): hoaa070.
  12. Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive response in controlled ovarian stimulation. Hum Reprod Update 2011; 17(1): 46-54.
  13. Li Y, Li X, Yang X, Cai S, Lu G, Lin G, et al. Cumulative Live Birth Rates in Low Prognosis Patients According to the POSEIDON Criteria: An Analysis of 26,697 Cyclesof in vitro Fertilization/Intracytoplasmic Sperm Injection. Front Endocrinol (Lausanne) 2019; 10: 642.
  14. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009; 30(5): 465-93.
  15. Esteves SC, Alviggi C, Humaidan P, Fischer R, Andersen CY, Conforti A, et al. The POSEIDON Criteria and Its Measure of Success through the Eyes of Clinicians and Embryologists. Front Endocrinol (Lausanne) 2019; 10: 814.
  16. Hasegawa Y, Kitahara Y, Osuka S, Tsukui Y, Kobayashi M, Iwase A. Effect of hypothyroidism and thyroid autoimmunity on the ovarian reserve: A systematic review and meta-analysis. Reprod Med Biol 2021; 21(1):e12427.
  17. Herman T, Csehely S, Orosz M, Bhattoa HP, Deli T, Torok P, Lagana AS, Chiantera V, Jakab A. Impact of Endocrine Disorders on IVF Outcomes: Results from a Large, Single-Centre, Prospective Study. Reprod Sci 2023; 30(6):1878-1890.
  18. Venables A, Wong W, Way M, Homer HA. Thyroid autoimmunity and IVF/ICSI outcomes in euthyroid women: a systematic review and meta-analysis. Reprod Biol Endocrinol 2020; 18(1):120.
World Journal of Peri & Neonatology
Volume 7, Issue 2
October 2025
Pages 78-83

Files

History

  • Receive Date: 31 December 2025
  • Accept Date: 31 December 2025

Share

How to cite

Statistics